Mannatech (NASDAQ:MTEX – Get Free Report) and BeOne Medicines (NASDAQ:ONC – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings and analyst recommendations.
Insider and Institutional Ownership
13.0% of Mannatech shares are owned by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are owned by institutional investors. 41.5% of Mannatech shares are owned by company insiders. Comparatively, 6.6% of BeOne Medicines shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Risk and Volatility
Mannatech has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, BeOne Medicines has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Mannatech | -1.50% | -22.75% | -4.75% |
| BeOne Medicines | 1.38% | 5.52% | 3.17% |
Valuation & Earnings
This table compares Mannatech and BeOne Medicines”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Mannatech | $117.87 million | 0.12 | $2.49 million | ($0.86) | -8.93 |
| BeOne Medicines | $3.81 billion | 9.72 | -$644.79 million | $0.51 | 662.33 |
Mannatech has higher earnings, but lower revenue than BeOne Medicines. Mannatech is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent ratings for Mannatech and BeOne Medicines, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Mannatech | 1 | 0 | 0 | 0 | 1.00 |
| BeOne Medicines | 1 | 1 | 13 | 0 | 2.80 |
BeOne Medicines has a consensus price target of $378.43, indicating a potential upside of 12.03%. Given BeOne Medicines’ stronger consensus rating and higher possible upside, analysts clearly believe BeOne Medicines is more favorable than Mannatech.
Summary
BeOne Medicines beats Mannatech on 11 of the 14 factors compared between the two stocks.
About Mannatech
Mannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas.
About BeOne Medicines
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
Receive News & Ratings for Mannatech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mannatech and related companies with MarketBeat.com's FREE daily email newsletter.
